Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.06 USD
0.00 (5.83%)
Updated Apr 23, 2024 03:30 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Aridis Pharmaceuticals falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -30.37 | -42.19 | -22.33 | -29.68 |
Depreciation/Amortization & Depletion | NA | 0.49 | 0.44 | 0.34 | 0.34 |
Net Change from Assets/Liabilities | NA | -1.30 | 10.52 | -0.62 | 18.22 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.06 | 8.31 | 2.14 | 2.96 |
Net Cash From Operating Activities | NA | -29.13 | -22.94 | -20.48 | -8.16 |
Property & Equipment | NA | -0.08 | -0.53 | -0.37 | -0.17 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.08 | -0.53 | -0.37 | -0.17 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 12.61 | 29.72 | 7.96 | 4.99 |
Issuance (Repayment) of Debt | NA | 3.20 | 5.00 | 0.72 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -1.03 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 14.78 | 34.72 | 8.68 | 4.99 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -14.43 | 11.25 | -12.17 | -3.34 |
Cash at Beginning of Period | NA | 19.99 | 8.73 | 20.90 | 24.24 |
Cash at End of Period | NA | 5.56 | 19.99 | 8.73 | 20.90 |
Diluted Net EPS | NA | -1.62 | -3.77 | -2.44 | -3.51 |
Fiscal Year End for Aridis Pharmaceuticals falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | 5.25 | 5.33 | -6.82 |
Depreciation/Amortization & Depletion | NA | NA | 0.21 | 0.15 | 0.09 |
Net Change from Assets/Liabilities | NA | NA | -16.79 | -14.95 | 1.88 |
Net Cash from Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | NA | 2.01 | 1.13 | 0.85 |
Net Cash From Operating Activities | NA | NA | -9.33 | -8.35 | -4.00 |
Property & Equipment | NA | NA | 0.01 | 0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | NA | 0.00 | 0.00 | 0.00 |
Investments | NA | NA | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | NA | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | NA | 0.01 | 0.01 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | 3.79 | 2.06 | 2.06 |
Issuance (Repayment) of Debt | NA | NA | 1.02 | 1.75 | -1.49 |
Increase (Decrease) Short-Term Debt | NA | NA | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | NA | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | NA | -0.52 | -0.52 | -0.31 |
Net Cash from Financing Activities | NA | NA | 4.29 | 3.29 | 0.26 |
Effect of Exchange Rate Changes | NA | NA | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | NA | -5.02 | -5.04 | -3.74 |
Cash at Beginning of Period | NA | NA | 5.56 | 5.56 | 5.56 |
Cash at End of Period | NA | NA | 0.54 | 0.52 | 1.82 |
Diluted Net EPS | NA | NA | 0.00 | 0.33 | -0.22 |